Page 12 - Read Online

survival (Italian experience). Am J Gastroenterol 2002;97:734-44. determines the efficacy of percutaneous ethanol injection for the
35. Bolondi L, Sofi a S, Siringo S, Gaiani S, Casali A, Zironi G, Piscaglia F, treatment of small hepatocellular carcinoma. Hepatology 1992;16:353-7.
Gramantieri L, Zanetti M, Sherman M. Surveillance programme of 55. Lencioni R, Crocetti L. A critical appraisal of the literature on local
cirrhotic patients for early diagnosis and treatment of hepatocellular ablative therapies for hepatocellular carcinoma. Clin Liver Dis
carcinoma: a cost effectiveness analysis. Gut 2001;48:251-9. 2005;9:301-14, viii.
36. Outwater EK. Imaging of the liver for hepatocellular cancer. Cancer 56. May JP, Li SD. Hyperthermia-induced drug targeting. Expert Opin Drug
Control 2010;17:72-82. Deliv 2013;10:511-27.
37. Colli A, Fraquelli M, Casazza G, Massironi S, Colucci A, Conte D, 57. Kulik LM, Atassi B, van Holsbeeck L, Souman T, Lewandowski RJ,
Duca P. Accuracy of ultrasonography, spiral CT, magnetic resonance, and Mulcahy MF, Hunter RD, Nemcek AA Jr, Abecassis MM, Haines KG
alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic 3rd, Salem R. Yttrium-90 microspheres (TheraSphere) treatment of
review. Am J Gastroenterol 2006;101:513-23. unresectable hepatocellular carcinoma: downstaging to resection, RFA
38. Davila JA, Morgan RO, Richardson PA, Du XL, McGlynn KA, and bridge to transplantation. J Surg Oncol 2006;94:572-86.
El-Serag HB. Use of surveillance for hepatocellular carcinoma among 58. Sangro B, Carpanese L, Cianni R, Golfi eri R, Gasparini D, Ezziddin S,
patients with cirrhosis in the United States. Hepatology 2010;52:132-41. Paprottka PM, Fiore F, Van Buskirk M, Bilbao JI, Ettorre GM,
39. Marrero JA, Hussain HK, Nghiem HV, Umar R, Fontana RJ, Lok AS. Salvatori R, Giampalma E, Geatti O, Wilhelm K, Hoffmann RT,
Improving the prediction of hepatocellular carcinoma in cirrhotic patients Izzo F, Iñarrairaegui M, Maini CL, Urigo C, Cappelli A, Vit A,
with an arterially-enhancing liver mass. Liver Transpl 2005;11:281-9. Ahmadzadehfar H, Jakobs TF, Lastoria S; European Network on
40. Mitchell DG, Bruix J, Sherman M, Sirlin CB. LI-RADS (Liver Imaging Radioembolization with Yttrium-90 Resin Microspheres (ENRY).
Reporting and Data System): Summary, discussion, and consensus Survival after yttrium-90 resin microsphere radioembolization of
of the LI-RADS Management Working Group and future directions. hepatocellular carcinoma across Barcelona clinic liver cancer stages: a
Hepatology 2015;61:1056-65. European evaluation. Hepatology 2011;54:868-78.
41. von Herbay A, Westendorff J, Gregor M. Contrast-enhanced ultrasound 59. Llovet JM, Real MI, Montaña X, Planas R, Coll S, Aponte J, Ayuso C,
with SonoVue: differentiation between benign and malignant focal liver Sala M, Muchart J, Solà R, Rodés J, Bruix J; Barcelona Liver Cancer
lesions in 317 patients. J Clin Ultrasound 2010;38:1-9. Group. Arterial embolisation or chemoembolisation versus symptomatic
42. Kim JI, Lee JM, Choi JY, Kim YK, Kim SH, Lee JY, Han JK, Choi BI. treatment in patients with unresectable hepatocellular carcinoma: a
The value of gadobenate dimeglumine-enhanced delayed phase MR randomised controlled trial. Lancet 2002;359:1734-9.
imaging for characterization of hepatocellular nodules in the cirrhotic 60. Llovet JM, Bruix J. Systematic review of randomized trials for
liver. Invest Radiol 2008;43:202-10. unresectable hepatocellular carcinoma: chemoembolization improves
43. Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the survival. Hepatology 2003;37:429-42.
BCLC staging classifi cation. Semin Liver Dis 1999;19:329-38. 61. Georgiades CS, Hong K, D’Angelo M, Geschwind JF. Safety and effi cacy of
44. Grieco A, Pompili M, Caminiti G, Miele L, Covino M, Alfei B, transarterial chemoembolization in patients with unresectable hepatocellular
Rapaccini GL, Gasbarrini G. Prognostic factors for survival in carcinoma and portal vein thrombosis. J Vasc Interv Radiol 2005;16:1653-9.
patients with early-intermediate hepatocellular carcinoma undergoing 62. Varela M, Real MI, Burrel M, Forner A, Sala M, Brunet M, Ayuso C,
non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging Castells L, Montañá X, Llovet JM, Bruix J. Chemoembolization
systems in a single Italian centre. Gut 2005;54:411-8. of hepatocellular carcinoma with drug eluting beads: effi cacy and
45. Marrero JA, Fontana RJ, Barrat A, Askari F, Conjeevaram HS, Su GL, doxorubicin pharmacokinetics. J Hepatol 2007;46:474-81.
Lok AS. Prognosis of hepatocellular carcinoma: comparison of 7 staging 63. Poon RT, Tso WK, Pang RW, Ng KK, Woo R, Tai KS, Fan ST. A phase
systems in an American cohort. Hepatology 2005;41:707-16. I/II trial of chemoembolization for hepatocellular carcinoma using a novel
46. Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical intra-arterial drug-eluting bead. Clin Gastroenterol Hepatol 2007;5:1100-8.
treatment for early hepatocellular carcinoma: resection versus 64. Li X, Feng GS, Zheng CS, Zhuo CK, Liu X. Expression of plasma vascular
transplantation. Hepatology 1999;30:1434-40. endothelial growth factor in patients with hepatocellular carcinoma and effect
47. Forner A, Bruix J. East meets the West – portal pressure predicts of transcatheter arterial chemoembolization therapy on plasma vascular
outcome of surgical resection for hepatocellular carcinoma. Nat Clin endothelial growth factor level. World J Gastroenterol 2004;10:2878-82.
Pract Gastroenterol Hepatol 2009;6:14-5. 65. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF,
48. Breitenstein S, Apestegui C, Petrowsky H, Clavien PA. “State of the art” de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C,
in liver resection and living donor liver transplantation: a worldwide Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I,
survey of 100 liver centers. World J Surg 2009;33:797-803. Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J;
49. Tung-Ping Poon R, Fan ST, Wong J. Risk factors, prevention, and SHARP Investigators Study Group. Sorafenib in advanced hepatocellular
management of postoperative recurrence after resection of hepatocellular carcinoma. N Engl J Med 2008;359:378-90.
carcinoma. Ann Surg 2000;232:10-24. 66. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J,
50. Poon RT. Prevention of recurrence after resection of hepatocellular Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H,
carcinoma: a daunting challenge. Hepatology 2011;54:757-9. Burock K, Zou J, Voliotis D, Guan Z. Effi cacy and safety of sorafenib
51. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, in patients in the Asia-Pacifi c region with advanced hepatocellular
Montalto F, Ammatuna M, Morabito A, Gennari L. Liver transplantation carcinoma: a phase III randomised, double-blind, placebo-controlled
for the treatment of small hepatocellular carcinomas in patients with trial. Lancet Oncol 2009;10:25-34.
cirrhosis. N Engl J Med 1996;334:693-9. 67. Park JW, Finn RS, Kim JS, Karwal M, Li RK, Ismail F, Thomas M,
52. Freeman RB, Wiesner RH, Edwards E, Harper A, Merion R, Wolfe R; Harris R, Baudelet C, Walters I, Raoul JL. Phase II, open-label study
United Network for Organ Sharing. Results of the fi rst year of the new of brivanib as fi rst-line therapy in patients with advanced hepatocellular
liver allocation plan. Liver Transpl 2004;10:7-15. carcinoma. Clin Cancer Res 2011;17:1973-83.
53. Graziadei IW, Sandmueller H, Waldenberger P, Koenigsrainer A,
Nachbaur K, Jaschke W, Margreiter R, Vogel W. Chemoembolization How to cite this article: Buell JF. Hepatoma Research: the beginning of
followed by liver transplantation for hepatocellular carcinoma impedes a new forum. Hepatoma Res 2015;1:1-5.
tumor progression while on the waiting list and leads to excellent
outcome. Liver Transpl 2003;9:557-63.
54. Vilana R, Bruix J, Bru C, Ayuso C, Solé M, Rodés J. Tumor size Source of Support: Nil. Confl ict of Interest: None declared.

Hepatoma Research | Volume 1 | Issue 1 | April 15, 2015 5